Evoke spinal cord stimulator overview The evoke spinal cord stimulator (SCS) is a rechargeable, implantable, closed loop stimulator for chronic pain management. The system is made up of an implantable closed loop stimulator (an external stimulator is used during an initial trial period), 1 or 2 leads connecting the stimulator to the spinal cord, a remote control for manually changing stimulation and a charging kit. The evoke stimulator (external or implantable) is programmed to deliver therapeutic SCS utilising feedback control by the Evoke Clinical interface and Evoke Clinical system Transceiver. The Evoke system utilises feedback control by recording activation of neural tissue and automatically adjusting stimulation to ensure it remains within the therapeutic range. The Evoke system is intended to replace conventional SCS for adults with chronic, intractable pain. The company claims the device offers patients improved pain relief and quality of life. The company also claim the technology has the potential to reduce costs related to opioid medication and the number of hospital visits.
 
Status In progress
Process MT
ID number 567

Provisional Schedule

Stakeholder registration opens 25 October 2021
Scope published 07 December 2021
Committee meeting: 1 22 April 2022
Draft guidance: 1 16 May 2022 - 15 June 2022
Committee meeting: 2 22 July 2022
Resolution 22 August 2022
Expected publication 04 October 2022

Project Team

Project lead Rebecca Brookfield

Email enquiries

Stakeholders

External assessment group KiTEC
Manufacturers Saluda Medical
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  University of Manchester Wounds Research Group
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital

For further information on how we develop guidance, please see our page about NICE medical technologies guidance